-
Standardized Tools for Constructing DAGs - Advancing Causal Inference and Risk Assessment in Pharmaceutical Studies
Mar 10, 2025, 14:00 PM -
Participation in a Patient Support Program is Associated With Improved Access to Efgartigimod Treatment for Generalized Myasthenia Gravis in Patients Facing Social Determinants of Health (SDOH) Challenges
Mar 10, 2025, 14:00 PM -
Assessing Differences in Clinical Burden Across Payers for Non-Obstructive Hypertrophic Cardiomyopathy
Mar 10, 2025, 14:00 PM -
Real-World (rw) Early Clinical Endpoints for Patients with Resectable Non-Small Cell Lung Cancer (NSCLC): A Database Evaluation Study
Mar 10, 2025, 14:00 PM -
What Does the Pan-Asian Evidence for Malignant Robotic-Assisted Procedures With da Vinci Surgical Systems Say? A systematic Literature Review and Meta-Analysis
Mar 10, 2025, 14:00 PM -
Balancing Baseline Characteristics With SMOTE and Propensity Score Weighting in a Comparative Study of PASCAL Transcatheter Valve Repair and Medical Therapy for Degenerative Mitral Regurgitation
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Dostarlimab in the Treatment of Newly Diagnosed Patients with Locally Advanced Rectal Cancer: Early Economic Modelling.
Mar 10, 2025, 14:00 PM -
Adoption of a Drug Adherence-Enhancing Application To Achieve Optimal Medication Adherence and Blood Pressure Control Among Hypertensive Patients: A Randomized Controlled Trial
Mar 10, 2025, 14:00 PM -
Real-World Study Evaluating Drug Tolerability and Health Care Resource Use (HCRU) With Acalabrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Mar 10, 2025, 14:00 PM -
Moving the Needle: Value and Use of Real-World Evidence in Oncology Clinical Pathways Decision-Making
Mar 10, 2025, 14:00 PM -
Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema Due to C1 Inhibitor Deficiency
Mar 10, 2025, 14:00 PM -
Estimating US Cancer Prevalence With Community Oncology EHR-Based Datasets via National Benchmarks From SEER and NPCR
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Tripalimumab for Metastatic or Recurrent Triple-Negative Breast Cancer in Japan
Mar 10, 2025, 14:00 PM -
Real-world Impact of the United States Preventive Services Task Force (USPSTF) Guidelines on HIV-1 Pre-Exposure Prophylaxis (PrEP) Ancillary Service Cost Sharing: Segmented Change Pre- and Post-Milestone USPSTF Timepoints
Mar 10, 2025, 14:00 PM -
Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System
Mar 10, 2025, 14:00 PM -
Impact of Cirrhosis on Health-Related Quality of Life and Activity Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in France, Italy, Germany, and Canada
Mar 10, 2025, 14:00 PM -
The Role of Real-World Evidence in Breast Cancer Drug Submissions to NICE: Insights and Challenges
Mar 10, 2025, 14:00 PM -
Physician, Patient and Caregiver Concordance in a Real-World US Generalized Myasthenia Gravis Population
Mar 10, 2025, 14:00 PM -
Revascularization and Patency in Lower Limb Peripheral Arterial Disease: A Systematic Review and Meta-Analysis Comparing Paclitaxel-Eluting with Bare Metal Stents
Mar 10, 2025, 14:00 PM -
Modeling in R: Tutorial for Beginner Using a Cost-Effectiveness Analysis Made With Microsoft Excel
Mar 10, 2025, 14:00 PM
